Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Cash from Investing Activities (2023 - 2025)

Historic Cash from Investing Activities for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $14.9 million.

  • Contineum Therapeutics' Cash from Investing Activities rose 14950.14% to $14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.4 million, marking a year-over-year increase of 16693.56%. This contributed to the annual value of -$69.7 million for FY2024, which is 636.13% down from last year.
  • As of Q3 2025, Contineum Therapeutics' Cash from Investing Activities stood at $14.9 million, which was up 14950.14% from $13.9 million recorded in Q2 2025.
  • Contineum Therapeutics' 5-year Cash from Investing Activities high stood at $14.9 million for Q3 2025, and its period low was -$44.5 million during Q2 2023.
  • Moreover, its 3-year median value for Cash from Investing Activities was $8.7 million (2024), whereas its average is -$8.3 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 20396.46% in 2024, then surged by 14950.14% in 2025.
  • Quarter analysis of 3 years shows Contineum Therapeutics' Cash from Investing Activities stood at $9.0 million in 2023, then tumbled by 203.96% to -$9.4 million in 2024, then skyrocketed by 259.15% to $14.9 million in 2025.
  • Its last three reported values are $14.9 million in Q3 2025, $13.9 million for Q2 2025, and $14.9 million during Q1 2025.